Antares Pharma, Inc. (ATRS): Price and Financial Metrics


Antares Pharma, Inc. (ATRS): $5.59

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ATRS Stock Price Chart Interactive Chart >

Price chart for ATRS

ATRS Price/Volume Stats

Current price $5.59 52-week high $5.60
Prev. close $5.59 52-week low $3.11
Day low $5.58 Volume 2,707,400
Day high $5.60 Avg. volume 3,291,313
50-day MA $4.86 Dividend yield N/A
200-day MA $3.91 Market Cap 955.06M

Antares Pharma, Inc. (ATRS) Company Bio


Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company was founded in 1979 and is based in Ewing, New Jersey.


ATRS Latest News Stream


Event/Time News Detail
Loading, please wait...

ATRS Latest Social Stream


Loading social stream, please wait...

View Full ATRS Social Stream

Latest ATRS News From Around the Web

Below are the latest news stories about Antares Pharma Inc that investors may wish to consider to help them evaluate ATRS as an investment opportunity.

Antares Pharma (NASDAQ:ATRS) Could Easily Take On More Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | February 18, 2022

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The

Yahoo | February 17, 2022

Henry Schein (HSIC) Q4 Earnings and Revenues Beat Estimates

Henry Schein (HSIC) delivered earnings and revenue surprises of 18.89% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 15, 2022

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®

PDUFA target action date set for March 28, 2022EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal perio

Yahoo | February 3, 2022

Arrow Financial Corp Buys iShares Core MSCI International Developed Markets , PowerShares QQQ ...

Glens Falls, NY, based Investment company Arrow Financial Corp (Current Portfolio) buys iShares Core MSCI International Developed Markets , PowerShares QQQ Trust Ser 1, Caterpillar Inc, Dollar Tree Inc, Activision Blizzard Inc, sells Netflix Inc, iShares iBonds Dec 2021 Term Corporate ETF, Lockheed Martin Corp, Gilead Sciences Inc, Goldman Sachs Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Arrow Financial Corp.

Yahoo | January 28, 2022

Read More 'ATRS' Stories Here

ATRS Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 77.46%
3-year 14.31%
5-year 223.12%
YTD 56.58%
2021 -10.53%
2020 -15.11%
2019 72.79%
2018 36.68%
2017 -14.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8713 seconds.